LWP Technologies (ASX:LWP)
Imagine a battery that outperforms Telsla’s much-publicised battery storage solution.
By now we have all heard how Tesla has changed the energy storage market: it is predicted that 50% of cars will be electric by 2025.
Yet there are more changes to come.
While many companies in the energy storage solution space now look to lithium-ion batteries to power their products, one ASX company has acquired the patents to a graphene-based technology that could surpass lithium-ion in cost, power and time of use.
This company has invested $1.6M for a 50% interest in a joint venture that has three patents all focused on ground-breaking graphene battery technology, that could provide greater driving range, decreased charging times and no hazardous side effects…
As an energy technologist, the acquisition of three graphene Aluminium-Graphene Synthesis and battery technology patents, gives this company a look at the future of energy storage.
The information on this page should not be the only trigger for your investment decision. Click on the links below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.
The graphene patents give this company a foot in the energy storage market that it expects to grow substantially in both the short and long term.
And the company expects to have its first prototype within six to 12 months.
If it can prove up the tech, then the energy storage market could once again undergo another step change…
A Better Battery than Tesla? ASX Stock Invests in Graphene Battery Tech
Jun 16, 2016
The electric car revolution is in full swing – ask any ASX listed lithium and graphite explorer. The rise in the development and manufacture of electric cars (EVs) is driving the increased requirement for graphite and lithium owing to their use in lithium ion batteries…
ASX Junior’s Under-Drilled Cuban Oil Asset Puts it in Multi-Billion Barrel Company
Nov 15, 2018
Zero Safety Issues for IMU’s Immunotherapy Cancer Treatment: Phase II Trial Imminent
Nov 13, 2018